论文部分内容阅读
目的:评价美施康定治疗晚期癌症病人中、重度癌痛的疗效。 方法:192例中、重度癌痛患者使用美施康定期间 ,观察用药前后及应用不同剂量药物后疼痛的缓解率及不良反应发生情况。 结果 :美施康定治疗后疼痛缓解率为 98.9%。不良反应主要为便秘 (34.4 % ) ,恶心、呕吐 (19.8% )。结论:美施康定对各类癌痛都有良好的镇痛效果 ,其产生的不良反应可以预防并进行有效处理。
OBJECTIVE: To evaluate the curative effect of midsagumin in the treatment of advanced cancer patients with severe cancer pain. Methods: In 192 cases of moderate and severe cancer patients during the use of Meishi Kangding period, before and after treatment and the application of different doses of pain relief rate of pain and adverse reactions. Results: The pain relief rate after treatment was 98.9%. The main adverse reactions were constipation (34.4%), nausea and vomiting (19.8%). Conclusion: Mischitard has good analgesic effect on all kinds of cancer pain, and its adverse reactions can be prevented and effectively treated.